Isoxazole-Pyridine Derivatives Selective GABA A α5 Inverse Agonists
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current GABA A receptor inverse agonists are non-selective, proconvulsant, and not suitable for cognitive enhancement in humans due to their effects on various receptor subunits, limiting their therapeutic application for neurological disorders.
Innovation Solution
Development of isoxazole-pyridine derivatives that act as selective inverse agonists for the GABA A α5 receptor, reducing activity on α1, α2, and α3 subunits to minimize proconvulsant effects and enhance cognitive function.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Difficulty of detecting and measuring
If conventional benzodiazepine receptor inverse agonists are used, then cognitive enhancement may be achieved, but proconvulsant activity and non-selectivity on GABA A receptor subunits occur
Solution Approach 1:
The invention segments the GABA A receptor subunit selectivity by designing compounds with specific affinity for α5-containing subunits while minimizing activity at α1, α2, and α3 subunits. This is achieved through structural modification of the inverse agonist core to create subunit-selective agents that cognitively enhance without proconvulsant effects
Solution Approach 2:
The patent applies local quality by introducing specific substituent patterns at defined positions on the inverse agonist scaffold (e.g., R1-R6 substituents in formula I) that confer selective binding to α5 subunits. These localized structural features enable the compound to differentiate between receptor subtypes, providing cognitive benefits while avoiding harmful convulsant activity associated with non-selective agents
2Adaptability or versatility
If non-selective GABA A receptor inverse agonists are used, then broad receptor coverage is achieved, but therapeutic selectivity for cognitive enhancement is reduced
Solution Approach 1:
The invention changes the binding parameters of inverse agonists by modifying molecular structure (formula I with specific R1-R6 substituents) to alter affinity and selectivity profiles. This enables preferential binding to α5-containing GABA A receptors while reducing interaction with other subunits, achieving therapeutic selectivity for cognitive enhancement applications
3Object-affected harmful factors
If GABA A α5 selective inverse agonists are developed, then proconvulsant activity is reduced, but synthesis complexity increases
Solution Approach 1:
The patent employs preliminary action by designing a systematic synthetic route (Scheme 1) that prepares key intermediates (compounds of formula II and III) before final coupling. This staged approach, starting from commercially available materials and proceeding through defined transformation steps, simplifies the overall synthesis of complex selective inverse agonists while maintaining product purity and selectivity
Data Source
AI summary
The present invention is concerned with isoxazole-pyridine derivatives of formula I, having affinity and selectivity for GABA A a5 receptor, their manufacture, pharmaceutical compositions containing them and their use as medicaments. The active compounds of the present invention are useful as cognitive enhancer or for the therapeutic and/or prophylactic treatment of cognitive disorders like Alzheimer's disease.